HealthQuill Clinical trials
Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.
Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

Read More
Stem cell therapies, which replace dead cells in the brain, can stop movement problems, rigidity and tremors in patients, two small trial studies show.
Drugs Health Research

Stem cell therapy revives hope for patients with Parkinson’s disease

HQ Team April 17, 2025: Stem cell therapies, which replace dead cells in the brain, can stop movement problems, rigidity and tremors in.

Read More
Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a drug-induced liver injury that was resolved after discontinuation of the oral drug.
Uncategorized

Pfizer stops development of an investigational drug to treat obesity

HQ Team April 15, 2025: Pfizer Inc. stopped its trial of danuglipron for treating chronic weight management after an asymptomatic patient developed a.

Read More
Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and Drug Administration, according to a statement.
Drugs Health Medical

Amgen gets US approval to treat immunoglobulin G4-related disease 

HQ Team April 4, 2025: Amgen Inc.’s treatment for adults living with immune-mediated inflammatory conditions was granted regulatory approval by the US Food and.

Read More
The US Food and Drug Administration has rejected the biotechnology company Aldeyra Therapeutics Inc’s investigational drug for treating dry eyes, over concerns with the data from the trial.
Drugs Health Medical

Aldeyra Therapeutics’ dry eye treatment rejected by USFDA

HQ Team April 3, 2025: The US Food and Drug Administration has rejected the biotechnology company Aldeyra Therapeutics Inc’s investigational drug for treating.

Read More
Grey matter in the human brain may be linked to the start of adolescent smoking and nicotine addiction — a study that may have implications for prevention and treatment.
Health Research

MIT’s 40Hz gamma stimulation shows promise in slowing Alzheimer’s progression

HQ Team March 15, 2025: A decade of research at MIT’s Picower Institute for Learning and Memory has brought hope to millions battling.

Read More
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.
Health Research

Aspirin shows promise in preventing cancer metastasis

HQ Team March 10, 2025: University of Cambridge scientists have uncovered the mechanism behind how aspirin could reduce the spread of certain cancers.

Read More
AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services and peptide-based drug discovery, for about $2.2 billion to mark its entry into the obesity treatment space.
Drugs Medical Pharma

AbbVie inks $2.2b deal with Denmark’s Gurba, enters weight-loss market

 HQ Team March 4, 2025: AbbVie Inc. will license a drug to treat obesity from Denmark’s Gurba A/S, a preclinical contract research services.

Read More
AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the Anglo-Swedish company.
Drugs Health Pharma

AstraZeneca says trial breast cancer drug improves survival rates

AstraZeneca Plc.’s end-stage trials of its investigational drug for advanced breast cancer have increased survival rates in patients, results show, according to the.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More